Document And Entity Information
Document And Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2015 | Apr. 13, 2016 | Jun. 30, 2015 | |
Document and Entity Information [Abstract] | |||
Entity Registrant Name | Entia Biosciences, Inc. | ||
Document Type | 10-K | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Common Stock, Shares Outstanding | 28,134,777 | ||
Entity Public Float | $ 1,663,019 | ||
Amendment Flag | false | ||
Entity Central Index Key | 1,408,299 | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Filer Category | Smaller Reporting Company | ||
Entity Well-known Seasoned Issuer | No | ||
Document Period End Date | Dec. 31, 2015 | ||
Document Fiscal Year Focus | 2,015 | ||
Document Fiscal Period Focus | FY |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 |
Current Assets: | ||
Cash | $ 24,133 | $ 99,462 |
Accounts receivable, net | 7,098 | 243,782 |
Inventory, net | 40,323 | 48,043 |
Prepaid expenses | 56,782 | 46,107 |
Total Current Assets | 128,336 | 437,394 |
Property and Equipment, net | 32,686 | 43,147 |
Patents and licenses, net | 232,584 | 342,834 |
Long-Term Inventory | 55,000 | 47,333 |
Total Assets | 448,606 | 870,708 |
Current Liabilities: | ||
Accounts payable and accrued expenses | 960,557 | 552,990 |
Line of credit | 58,195 | 16,179 |
Short-term convertible notes payable, net of discount related-party | 0 | 9,399 |
Short-term convertible notes payable, net of discount | 181,981 | 357,646 |
Notes payable | 39,061 | 51,030 |
Total Current Liabilities | 1,239,794 | 987,244 |
Total Liabilities | 1,239,794 | 987,244 |
Stockholders' Equity (Deficit): | ||
Preferred stock, $0.001 par value, 5,000,000 shares authorized, Series A preferred stock, 350,000 shares designated, 191,307 and 200,807 shares issued and outstanding, respectively, aggregate liquidation value of $956,535 and $1,004,035 respectively | 191 | 201 |
Common stock, $0.001 par value, 150,000,000 shares authorized, 28,107,337 and 15,512,927 shares issued and outstanding, respectively | 28,108 | 15,514 |
Additional paid-in capital | 12,309,450 | 10,771,035 |
Deferred compensation | (51,945) | (86,344) |
Accumulated deficit | (13,076,992) | (10,816,942) |
Total Stockholders' Equity (Deficit) | (791,188) | (116,536) |
Total Liabilities and Stockholders' Equity (Deficit) | $ 448,606 | $ 870,708 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 |
Preferred stock, par value (in Dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
Common stock par value (in Dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 150,000,000 | 150,000,000 |
Common stock, shares issued | 28,107,337 | 15,512,927 |
Common stock, shares outstanding | 28,107,337 | 15,512,927 |
Series A Preferred Stock [Member] | ||
Preferred stock, shares authorized | 350,000 | 350,000 |
Preferred stock, shares issued | 191,307 | 200,807 |
Preferred stock, shares outstanding | 191,307 | 200,807 |
Preferred stock, aggregate liquidation value (in Dollars) | $ 956,535 | $ 1,004,035 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
REVENUES | $ 346,910 | $ 656,342 |
COST OF GOODS SOLD | 131,007 | 245,471 |
GROSS PROFIT | 215,903 | 410,871 |
OPERATING EXPENSES | ||
Advertising and promotion | 127,127 | 125,728 |
Professional fees | 231,125 | 156,561 |
Consulting fees | 344,112 | 400,352 |
Impairment of licenses | 110,000 | 27,080 |
General and administrative | 1,429,495 | 1,499,164 |
Total Operating Expenses | 2,241,859 | 2,208,885 |
LOSS FROM OPERATIONS | (2,025,956) | (1,798,014) |
OTHER INCOME (EXPENSES) | ||
Interest expense | (149,284) | (339,709) |
Other income (expense) | (35,895) | 7,298 |
Loss on write-off of debt discount | (23,321) | (100,000) |
Loss on settlement/conversion of notes payable | (32,500) | (169,187) |
Gain on settlement of accounts payable | 6,906 | 103,021 |
NET LOSS | $ (2,260,050) | $ (2,296,591) |
NET LOSS PER COMMON SHARE - BASIC AND DILUTED: (in Dollars per share) | $ (0.09) | $ (0.24) |
Weighted common shares outstanding - basic and diluted (in Shares) | 24,289,381 | 9,442,352 |
CONSOLIDATED STATEMENT OF STOCK
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) | Conversion of Convertible Debt [Member]Common Stock [Member] | Conversion of Convertible Debt [Member]Additional Paid-in Capital [Member] | Conversion of Convertible Debt [Member]Retained Earnings [Member] | Preferred Stock [Member]Conversion of Preferred Stock [Member] | Preferred Stock [Member] | Common Stock [Member]Conversion of Accounts Payable [Member] | Common Stock [Member]Conversion of Accrued Compensation [Member] | Common Stock [Member]Stock Issued for Future Services [Member] | Common Stock [Member]Conversion of Warrants [Member] | Common Stock [Member]Conversion of Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member]Warrants Issued for Convertible Notes [Member] | Additional Paid-in Capital [Member]Conversion of Accounts Payable [Member] | Additional Paid-in Capital [Member]Conversion of Accrued Compensation [Member] | Additional Paid-in Capital [Member]Stock Issued for Future Services [Member] | Additional Paid-in Capital [Member]Warrants Issued for Conversion of Accrued Salary [Member] | Additional Paid-in Capital [Member]Warrants Issued for Services [Member] | Additional Paid-in Capital [Member]Conversion of Warrants [Member] | Additional Paid-in Capital [Member]Conversion of Preferred Stock [Member] | Additional Paid-in Capital [Member] | Deferred Compensation, Share-based Payments [Member]Stock Issued for Future Services [Member] | Deferred Compensation, Share-based Payments [Member]Warrants Issued for Services [Member] | Deferred Compensation, Share-based Payments [Member] | Stock Subscriptions [Member] | Retained Earnings [Member]Warrants Issued for Convertible Notes [Member] | Retained Earnings [Member]Conversion of Accounts Payable [Member] | Retained Earnings [Member]Conversion of Accrued Compensation [Member] | Retained Earnings [Member]Warrants Issued for Conversion of Accrued Salary [Member] | Retained Earnings [Member]Warrants Issued for Services [Member] | Retained Earnings [Member] | Total |
Balance at Dec. 31, 2013 | $ 282 | $ 8,298 | $ 7,793,760 | $ (182,576) | $ (8,520,351) | $ (949,587) | |||||||||||||||||||||||||
Balance (in Shares) at Dec. 31, 2013 | 281,969 | 8,297,645 | |||||||||||||||||||||||||||||
Issuance of warrants | $ 88,600 | $ 91,863 | $ 153,010 | $ (153,010) | $ 88,600 | $ 91,863 | |||||||||||||||||||||||||
Amortization of deferred compensation | 293,492 | 293,492 | |||||||||||||||||||||||||||||
Net loss | (2,296,591) | (2,296,591) | $ (2,296,591) | ||||||||||||||||||||||||||||
Beneficial conversion feature in connection with convertible notes payable | 188,300 | 188,300 | |||||||||||||||||||||||||||||
Issuance of common stock for cash | $ 525 | 224,475 | 225,000 | ||||||||||||||||||||||||||||
Issuance of common stock for cash (in Shares) | 525,000 | ||||||||||||||||||||||||||||||
Issuance of common stock for conversion of securities | $ 2,634 | $ 930,650 | $ 933,284 | $ (81) | $ 345 | $ 2,592 | $ 812 | $ 132,583 | $ 775,178 | $ (731) | $ 132,928 | $ 777,770 | |||||||||||||||||||
Issuance of common stock for conversion of securities (in Shares) | 2,633,579 | (81,162) | 344,530 | 2,592,570 | 811,620 | ||||||||||||||||||||||||||
Stock compensation | 227,570 | 227,570 | |||||||||||||||||||||||||||||
Issuance of common stock for services | $ 68 | $ 240 | $ 44,182 | 121,595 | $ (44,250) | 121,835 | |||||||||||||||||||||||||
Issuance of common stock for services (in Shares) | 68,283 | 239,700 | |||||||||||||||||||||||||||||
Receipt of stock subscription receivable, less write-off of $9,000 | 49,000 | ||||||||||||||||||||||||||||||
Balance at Dec. 31, 2014 | $ 201 | $ 15,514 | 10,771,035 | (86,344) | (10,816,942) | (116,536) | (116,536) | ||||||||||||||||||||||||
Balance (in Shares) at Dec. 31, 2014 | 200,807 | 15,512,927 | |||||||||||||||||||||||||||||
Issuance of warrants | $ 10,000 | $ 7,891 | $ 10,000 | $ 7,891 | |||||||||||||||||||||||||||
Amortization of deferred compensation | 102,288 | 102,288 | |||||||||||||||||||||||||||||
Deferral of offering fees | (26,700) | (26,700) | |||||||||||||||||||||||||||||
Net loss | (2,260,050) | (2,260,050) | (2,260,050) | ||||||||||||||||||||||||||||
Issuance of common stock for cash | $ 5,348 | 554,825 | 560,173 | ||||||||||||||||||||||||||||
Issuance of common stock for cash (in Shares) | 5,347,901 | ||||||||||||||||||||||||||||||
Issuance of common stock for conversion of securities | $ 3,069 | $ 318,632 | $ 321,701 | $ (10) | $ 554 | $ 2,051 | $ 95 | $ 130,054 | $ (2,051) | $ (85) | $ 130,608 | ||||||||||||||||||||
Issuance of common stock for conversion of securities (in Shares) | 3,068,882 | (9,500) | 554,521 | 2,050,923 | 95,000 | ||||||||||||||||||||||||||
Stock compensation | $ 1,550 | 555,394 | 556,944 | ||||||||||||||||||||||||||||
Stock compensation (in Shares) | 1,550,000 | ||||||||||||||||||||||||||||||
Cancellation of shares issued to executives as compensation | $ (1,000) | (199,000) | (200,000) | ||||||||||||||||||||||||||||
Cancellation of shares issued to executives as compensation (in Shares) | (1,000,000) | ||||||||||||||||||||||||||||||
Issuance of common stock for services | $ 927 | 121,566 | 122,493 | ||||||||||||||||||||||||||||
Issuance of common stock for services (in Shares) | 927,183 | ||||||||||||||||||||||||||||||
Balance at Dec. 31, 2015 | $ 191 | $ 28,108 | $ 12,309,450 | $ (51,945) | $ (13,076,992) | $ (791,188) | $ (791,188) | ||||||||||||||||||||||||
Balance (in Shares) at Dec. 31, 2015 | 191,307 | 28,107,337 |
CONSOLIDATED STATEMENT OF STOC6
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals) | 12 Months Ended |
Dec. 31, 2014USD ($) | |
Stock Subscriptions [Member] | |
Stock subscription receivable, write-off | $ 9,000 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
CASH FLOWS USED IN OPERATING ACTIVITIES: | ||
Net loss | $ (2,260,050) | $ (2,296,591) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Bad debt expense | 0 | 30,022 |
Depreciation/amortization | 31,996 | 38,047 |
Gain on settlement of accounts payable | (6,906) | (103,021) |
Impairment of licenses | 110,000 | 27,080 |
Loss on write-off of debt discount | 23,321 | 100,000 |
Amortization of discount on convertible notes | 113,937 | 120,387 |
Loss on conversion of notes payable | 32,500 | 169,187 |
Stock-based compensation | 589,616 | 642,897 |
Loss on sale of stock subscription receivable | 0 | 12,965 |
Changes in operating assets and liabilities: | ||
Accounts receivable | 236,684 | (262,607) |
Inventory | 53 | 43,565 |
Prepaid expenses | 38,507 | 31,668 |
Accounts payable and accrued expenses | 553,777 | 766,117 |
NET CASH USED IN OPERATING ACTIVITIES | (536,565) | (680,284) |
CASH FLOWS USED IN INVESTING ACTIVITIES: | ||
Purchase of property and equipment | (8,051) | (4,607) |
Acquisition of patents and patents pending (net) | (13,235) | (40,857) |
NET CASH USED IN INVESTING ACTIVITIES | (21,286) | (45,464) |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Proceeds from issuance of common stock | 560,173 | 225,000 |
Proceeds from convertible notes payable and notes payable | 100,000 | 591,500 |
Payment on notes payable | (177,651) | (43,176) |
Payment on convertible note payable - related party | 0 | (40,000) |
Proceeds from sale of stock subscription receivable | 0 | 40,000 |
Proceeds from convertible note payable-related party | 0 | 15,000 |
NET CASH PROVIDED BY FINANCING ACTIVITIES | 482,522 | 788,324 |
NET CHANGE IN CASH | (75,329) | 62,576 |
Cash at beginning of period | 99,462 | 36,886 |
Cash at end of period | 24,133 | 99,462 |
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION: | ||
Interest paid | 37,834 | 843 |
SUPPLEMENTAL DISCLOSURE OF NONCASH FLOWS FINANCING AND INVESTING ACTIVITIES: | ||
Issuance of note payable for insurance | 0 | 43,313 |
Issuance of warrants for accrued salary | 0 | 91,863 |
Stock Issued for Accounts Payable [Member] | ||
SUPPLEMENTAL DISCLOSURE OF NONCASH FLOWS FINANCING AND INVESTING ACTIVITIES: | ||
Stock issued | 130,608 | 132,928 |
Covnersion of Convertible Notes Payable and Acrrued Interest [Member] | ||
SUPPLEMENTAL DISCLOSURE OF NONCASH FLOWS FINANCING AND INVESTING ACTIVITIES: | ||
Conversion of convertible notes payable, accounts payable and accrued interest to preferred and common stock | 321,701 | 1,711,054 |
Stock Issued for Services Rendered [Member] | ||
SUPPLEMENTAL DISCLOSURE OF NONCASH FLOWS FINANCING AND INVESTING ACTIVITIES: | ||
Stock issued | $ 122,493 | $ 0 |
NOTE 1 - ORGANIZATION AND OPERA
NOTE 1 - ORGANIZATION AND OPERATIONS | 12 Months Ended |
Dec. 31, 2015 | |
Disclosure Text Block [Abstract] | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | NOTE 1 – ORGANIZATION AND OPERATIONS Entia Biosciences, Inc. (“We” or “the Company”) engage in the development, production and distribution of organic dietary nutraceutical supplement products, principally in the United States of America. We are also engaged in the discovery, scientific evaluation and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics and other products developed and sold by Entia and by third parties. We have a history of incurring net losses and net operating cash flow deficits. We are also developing new organic medical foods products. At December 31, 2015, we had cash and cash equivalents of $24,133. These conditions raise substantial doubt about our ability to continue as a going concern. Based on our cash on hand, planned financings, and results from future operations, we believe that we will have sufficient funds to continue operations through 2016. In order for us to continue as a going concern beyond this point and ultimately to achieve profitability, we will likely be required to obtain capital from external sources, increase revenues and reduce operating costs. The issuance of equity securities will cause dilution to our shareholders. If external sources of financing are not available or are inadequate to fund our operations, we will be required to reduce operating costs including personnel costs, which could jeopardize our future strategic initiatives and business plans. The accompanying consolidated financial statements have been prepared assuming that the Company continues as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein. |
NOTE 2 - SUMMARY OF SIGNIFICANT
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Dec. 31, 2015 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies [Text Block] | NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation and principles of consolidation The accompanying consolidated financial statements and related notes have been prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Material intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements include the accounts of Entia and Total Nutraceutical Solutions, a wholly-owned subsidiary, as of December 31, 2015 and 2014. Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash We consider all highly liquid, short-term investments with original maturities of three months or less when purchased to be cash equivalents. Accounts receivable Accounts receivable are recorded at the invoiced amount, net of allowance for doubtful accounts. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses based on specific identification of accounts in our existing accounts receivable. Outstanding account balances are reviewed individually for collectibility. We determine the allowance based on historical write-off experience, customer specific facts and economic conditions. Bad debt expense is included in general and administrative expenses, if any. We generally consider accounts greater than 30 days old to be past due. Account balances are charged off against allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts was $5,736 and $30,022 at December 31, 2015 and 2014, respectively. Inventory Inventory consists of finished goods and raw materials to be used in the production of our dietary supplement products, is stated at the lower of cost or market using the average cost method. We regularly review our inventory on hand and, when necessary, record a provision for excess or obsolete inventory. The portion of inventory that is not expected to be used in production of our products for more than 12 months is a long-term asset. Property and equipment Property and equipment are recorded at cost. Additions and improvements that increase the value or extend the life of an asset are capitalized. Maintenance and repairs are expensed as incurred. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in the consolidated statement of operations. Depreciation is computed on a straight-line basis over the following estimated useful lives of the assets: Office equipment 3 years Production equipment 5 to 7 years Leasehold improvements Lesser of lease term or useful life of improvement Patents Patents, once issued or purchased, are amortized using the straight-line method over their economic remaining useful lives. All internally developed process costs incurred to the point when a patent application is to be filed are expensed as incurred and classified as research and development costs. Patent application costs, generally legal costs, are capitalized pending disposition of the individual patent application, and are subsequently either amortized based on the initial patent life granted, generally 15 to 20 years for domestic patents and 5 to 20 years for foreign patents, or expensed if the patent application is rejected. The costs of defending and maintaining patents are expensed as incurred. Upon becoming fully amortized, the related cost and accumulated amortization are removed from the accounts. Licenses Licenses that allow us to use certain technology in the production of our products are amortized on a straight-line basis over their remaining useful life (typically 15-17 years). Long-lived assets, including licenses, property and equipment and patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We assess the recoverability of our long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives. We have recorded an impairment on our licenses in the amount of $110,000 and $27,080 on December 31, 2015 and 2014, respectively. Discount on convertible notes payable We allocate the proceeds received from convertible notes between convertible notes payable and warrants, if applicable. The resulting discount for warrants is amortized using the effective interest method over the life of the debt instrument. After allocating a portion of the proceeds to the warrants, the effective conversion price of the convertible note payable can be determined. If the effective conversion price is lower than the market price at the date of issuance, a beneficial conversion feature is recorded as an additional discount to the convertible note payable. The beneficial conversion feature discount is amortized using the effective interest method over the life of the debt instrument. The amortization is recorded as interest expense on the consolidated statement of operations. Fair value of financial instruments The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable and accounts payable approximate their fair values determined based on level 1 inputs in the fair value hierarchy because of the short maturity of these instruments. Due to conversion features and other terms, it is not practical to estimate the fair value of notes payable and convertible notes. Fair value measurements We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions. We do not have any assets or liabilities measured at fair value on a recurring or a non-recurring basis. Consequently, we did not have any fair value adjustments for assets and liabilities measured at fair value at December 31, 2015 or 2014, nor any gains or losses reported in the consolidated statement of operations that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date for the years ended December 31, 2015 and 2014. Revenue recognition We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectibility of amounts is reasonably assured. Revenues from the sale of products, including shipping and handling fees but excluding statutory taxes collected from customers, as applicable, are recognized when shipment has occurred. We sell our products directly to customers and distributors. Persuasive evidence of an arrangement is demonstrated via order and invoice, product delivery is evidenced by a bill of lading from the third party carrier and title transfers upon shipment, the sales price to the customer is fixed upon acceptance of the order and there is no separate sales rebate, discount, or volume incentive. Allowances for product returns, primarily in connection with one distribution agreement, are provided at the time the sale is recorded. This allowance is based upon historical return rates for the Company and relevant industry patterns, which reflects anticipated returns of unopened product in its original packaging to be received over a period of 120 days following the original sale. Shipping and handling costs Amounts charged to customers for shipping products are included in revenues and the related costs are classified in cost of goods sold as incurred. In 2015 and 2014, we incurred $27,848 and $34,286, respectively, in shipping costs included in cost of goods sold. Advertising costs Costs associated with the advertising of our products are expensed as incurred. Research and development Research and development costs are charged to expense as incurred. Research and development costs consist primarily of material and testing costs for research and development as well as research and development arrangements with unrelated third party research and development institutions. These research and development arrangements usually involve one specific research and development project. We may make non-refundable advances upon signing of these arrangements. Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or as the related services are performed. Management periodically evaluates whether the goods will be delivered or services will be rendered. If management does not expect the goods to be delivered or services to be rendered, the capitalized advance payment is charged to expense. Research and development expense was $ 73,394 Equity instruments issued to parties other than employees for acquiring goods or services We account for all transactions in which goods or services are the consideration received for the issuance of equity instruments based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. Currently such transactions are primarily awards of warrants to purchase common stock. The fair value of each warrant award is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The assumptions used to determine the fair value of our warrants are as follows: - The expected life of warrants issued represents the period of time the warrants are expected to be outstanding. - The expected volatility is generally based on the historical volatility of comparable companies’ stock over the contractual life of the warrant. - The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual life of the warrant. - The expected dividend yield is based on our current dividend yield as the best estimate of projected dividend yield for periods within the contractual life of the warrant. During 2015 and 2014, we issued restricted common stock, warrants and non-statutory stock options to attorneys, scientific, marketing and financial consultants and our external contract accountants. The value of these instruments equal $384,922 of the total $589,616 for 2015 and $257,689 of the total $642,897 for 2014. Income taxes We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in our consolidated statements of income in the period that includes the enactment date. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in our consolidated financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Should they occur, our policy is to classify interest and penalties related to tax positions as income tax expense. The tax years that are open to examination are 2012, 2013, 2014 and 2015. Net loss per common share Basic and diluted net loss per share has been computed by dividing our net loss by the weighted average number of common shares issued and outstanding. Convertible preferred stock, options and warrants to purchase our common stock as well as debt which are convertible into common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share for 2015 and 2014. The following table presents a reconciliation of basic loss per share and excluded dilutive securities: For the Years Ended 2015 2014 Numerator: Net loss allocable to common stockholders $ (2,260,050 ) $ (2,296,591 ) Denominator: Weighted-average common shares outstanding 24,289,381 9,442,352 Basic and diluted net loss per share $ (0.09 ) $ (0.24 ) Common stock warrants 18,925,825 7,110,701 Series A convertible preferred stock 1,913,070 2,008,070 Stock options 2,898,220 2,866,470 Convertible debt including interest 601,775 1,317,604 Excluded dilutive securities 24,338,890 13,302,845 Reclassifications Certain reclassifications have been made to prior period financial statements and footnotes in order to conform to the current period's presentation. Segments We have determined that we operate in one segment for financial reporting purposes. Recently issued accounting pronouncements In May 2014, the FASB issued new accounting guidance related to revenue recognition. This new standard will replace all current U.S. GAAP guidance on this topic and eliminate all industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective for Entia in the first quarter of 2018, and can be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. We are evaluating the impact of adopting this new accounting standard on our financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This update requires organizations to recognize lease assets and lease liabilities on the balance sheet and also disclose key information about leasing arrangements. This ASU is effective for annual reporting periods beginning on or after December 15, 2018, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual period. We are currently evaluating the impact the adoption of this ASU will have on our consolidated financial statements. |
NOTE 3 - INVENTORY
NOTE 3 - INVENTORY | 12 Months Ended |
Dec. 31, 2015 | |
Inventory Disclosure [Abstract] | |
Inventory Disclosure [Text Block] | NOTE 3 – INVENTORY Inventory consists of the following at: December 31, 2015 December 31, 2014 Raw materials $ 27,313 $ 202,591 Finished goods 219,074 43,849 246,387 246,440 Less reserve for excess and obsolete inventory (151,064 ) (151,064 ) 95,323 95,376 Less current portion (40,323 ) (48,043 ) $ 55,000 $ 47,333 |
NOTE 4 - PROPERTY AND EQUIPMENT
NOTE 4 - PROPERTY AND EQUIPMENT | 12 Months Ended |
Dec. 31, 2015 | |
Property, Plant and Equipment [Abstract] | |
Property, Plant and Equipment Disclosure [Text Block] | NOTE 4 – PROPERTY AND EQUIPMENT Property and equipment, stated at cost, consists of the following at: December 31, 2015 December 31, 2014 Office equipment $ 31,658 $ 27,507 Production equipment 90,899 86,999 Leasehold improvements 16,328 16,328 138,885 130,834 Less: accumulated depreciation (106,199 ) (87,687 ) $ 32,686 $ 43,147 Depreciation expense was $18,512 and $23,605 for the years ended December 31, 2015 and 2014, respectively. |
NOTE 5 - PATENTS AND LICENSES,
NOTE 5 - PATENTS AND LICENSES, NET | 12 Months Ended |
Dec. 31, 2015 | |
Disclosure Text Block [Abstract] | |
Intangible Assets Disclosure [Text Block] | NOTE 5 – PATENTS AND LICENSES, NET Our identifiable long-lived intangible assets are patents and licenses. During 2015 and 2014, management analyzed our intangibles for possible impairment. We have recorded for 2015 and 2014 an impairment in the amount of $110,000 and $27,080, respectively. The licenses are being amortized over an economic useful life of 15-17 years. The gross carrying amounts and accumulated amortization related to these intangible assets consist of the following at: December 31, 2015 December 31, 2014 Licenses and amortizable patents $ 97,244 $ 207,244 Unamortized patents 179,393 166,159 Accumulated amortization (44,053 ) (30,569 ) Patents and Licenses, net $ 232,584 $ 342,834 Amortization expense for licenses and amortizable patents were $13,484 and $14,442 for the years ended December 31, 2015 and 2014, respectively. Annual aggregate amortization expense for our licenses and amortizable patents for each of the next five years through December 31, 2020, is $4,396 per year and for years 2021 and later it is estimated to be $31,214. |
NOTE 6 - ACCOUNTS PAYABLE AND A
NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES | 12 Months Ended |
Dec. 31, 2015 | |
Payables and Accruals [Abstract] | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | NOTE 6 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accrued expenses (included with accounts payable) consisted of the following at: December 31, 2015 December 31, 2014 Executive compensation $ 327,285 $ 153,432 Other accruals 38,022 19,725 $ 365,307 $ 173,157 |
NOTE 7 - NOTES PAYABLE
NOTE 7 - NOTES PAYABLE | 12 Months Ended |
Dec. 31, 2015 | |
Debt Disclosure [Abstract] | |
Debt Disclosure [Text Block] | NOTE 7 – NOTES PAYABLE Notes payable consists of the following at: December 31, 2015 December 31, 2014 Notes payable - current 7.85% unsecured, $473 due monthly $ - $ 2,304 5.86% unsecured, $781 due monthly 2,687 - 4.15% unsecured, $3,436 due monthly 36,374 - 4.15% unsecured, $3,436 due monthly - 23,726 10.00% unsecured, interest only, due on demand. Note was settled on May 29, 2015 in exchange for 250,000 shares of common stock. In addition, 500,000 3-year warrants were granted and vested with an exercise price ranging from $0.125 - $0.15. We calculated and posted a loss on the settlement in the amount of $32,500. - 25,000 $ 39,061 $ 51,030 Convertible notes payable, net 8% secured due on December 26, 2015 (net of discount related to beneficial conversion feature of $0 in 2015 and $7,746 in 2014), convertible into preferred stock at $5.00 per share. During 2016, this note was exchanged with an effective date of December 26, 2015. Refer to Note 13 – Subsequent Events for further disclosure $ 50,000 $ 42,254 6% unsecured, convertible into common stock at $2.00 per share, due on demand 50,000 50,000 10% unsecured due December 31, 2015 (net of discount related to warrants of $0 in 2015 and $1,727 in 2014) convertible price to be determined by the purchase price paid by investors in future offerings, not to exceed $1.50 per share. During 2016, this note was exchanged with an effective date of December 31, 2015. Refer to Note 13 – Subsequent Events for further disclosure. 10,000 8,273 10% unsecured due October 16, 2015 (net of discount related to warrants of $0 in 2015 and $1,805 in 2014) convertible price to be determined by the purchase price paid by investors in future offerings, not to exceed $1.50 per share. During 2016, this note was exchanged with an effective date of October 16, 2015. Refer to Note 13 – Subsequent Events for further disclosure. 10,000 8,195 8% unsecured due November 25, 2018 (net of discount related to warrants of $3,019 in 2015 and $0 in 2014) convertible into common stock at $0.10 per share. 46,981 - 0% unsecured due November 3, 2015 (net of discount related to beneficial conversion feature of $0 in 2015 and $2,738 in 2014 and net of discount related to warrants of $0 in 2015 and $2,863 in 2014 and convertible into common stock at $0.30 per share.) During 2016, this note was exchanged with an effective date of November 3, 2015. Refer to Note 13 – Subsequent Events for further disclosure. 15,000 9,399 Nine convertible notes payable (net of debt discount of $90,076) with interest between 8% to 10% were paid in cash or converted into common stock during 2015. - 239,525 $ 181,981 $ 357,646 Line of Credit |
NOTE 8 - RELATED PARTY TRANSACT
NOTE 8 - RELATED PARTY TRANSACTIONS | 12 Months Ended |
Dec. 31, 2015 | |
Related Party Transactions [Abstract] | |
Related Party Transactions Disclosure [Text Block] | NOTE 8 – RELATED PARTY TRANSACTIONS Debt agreements from board member Common stock issued On April 17, 2015, the board of directors authorized and granted to its executives and board or directors for the year end 2015, restricted common stock bonuses as follows: · Marvin Hausman, former CEO and director, 600,000 shares valued at $120,000 · Devin Andres, former COO, 550,000 shares valued at $110,000 · Philip Sobol, former director, 200,000 shares valued at $40,000, and · Elliott Shelton, director, 200,000 shares valued at $40,000. |
NOTE 9 - STOCKHOLDERS' EQUITY (
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) | 12 Months Ended |
Dec. 31, 2015 | |
Stockholders' Equity Note [Abstract] | |
Stockholders' Equity Note Disclosure [Text Block] | NOTE 9 – STOCKHOLDERS’ EQUITY (DEFICIT) Preferred Stock On May 26, 2011, our board of directors designated 350,000 shares of preferred stock as Series A preferred stock, $0.001 par value. The Series A preferred stock is entitled to a liquidation preference in the amount of $5 per share, votes on an as converted basis with the common stock on all matters as to which holders of common stock shall be entitled to vote, and is convertible into common stock on a one-for-ten basis. Common stock The Company is authorized to issue 150,000,000 shares of common stock at $0.001 par value. Stock incentive plan The Entia Biosciences, Inc. 2010 Stock Incentive Plan was adopted by the board of directors on September 17, 2010 and approved by the stockholders on October 21, 2010. Initially 15 million shares were reserved for issuance under the Plan. On January 1, 2012, 500,000 additional shares were automatically added to the shares reserved for issuance under the Plan, pursuant to an evergreen provision in the Plan. On February 15, 2012, pursuant to a 1:10 reverse stock split the number of shares reserved for issuance under the Plan was reduced from 15,500,000 shares to 1,550,000 shares. During 2013 and 2014, an additional 100,000 shares were automatically added to the shares reserved for issuance under the Plan and the shareholders, on two separate occasions, approved an additional 1.5 million shares each to be added bringing the total shares reserved to 4,650,000 shares. On January 1, 2015, another 50,000 shares were automatically added to the shares reserved for issuance bringing the total to 4,700,000 shares. Stock options are granted at or below the closing price of our stock on the date of grant for terms ranging from four to fifteen years and generally vest over a five-year period. The fair value of the option grants was calculated at the date of the grants using the Black-Scholes option pricing model with the following assumptions: December 31, 2015 December 31, 2014 Expected dividend yield - - Expected stock price volatility 187.7% - 201.79 % 182.94% - 216.96 % Risk-free interest rate 1.47% - 1.68 % 0.28% - 1.91 % Expected term (in years) 5 years 3 - 7 years Weighted-average granted date fair value $ 0.16 $ 0.45 A summary of option activity under the stock option plan as of December 31, 2015, and changes during the year then ended is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Price Exercise Contractual Term Intrinsic Shares Range Price (Years) Value Outstanding, December 31, 2013 2,352,099 $ 0.38 - $1.00 $ 0.51 7.90 199,505 Exercisable, December 31, 2013 1,810,344 $ 0.38 - $1.00 $ 0.52 7.88 138,707 Granted 624,571 $ 0.40-$0.75 $ 0.52 6.49 - Exercised - - $ - - - Expired/Forfeited 110,200 $ 0.40-$0.50 $ 0.48 9.51 - Outstanding, December 31, 2014 2,866,470 $ 0.30 - $1.00 $ 0.48 8.96 - Exercisable, December 31, 2014 2,321,001 $ 0.38 - $1.00 $ 0.47 9.50 - Granted 50,000 $ 0.09 - $0.20 $ 0.16 5.00 - Exercised - - $ - - - Expired/Forfeited 18,250 $ 0.40 - $0.50 $ 0.49 8.73 - Outstanding, December 31, 2015 2,898,220 $ .0.20 - $1.00 $ 0.43 11.25 - Exercisable, December 31, 2015 2,661,493 $ 0.096 - $1.00 $ 0.42 11.66 - The range of exercise prices for options outstanding under the 2010 Stock Incentive Plan at December 31, 2015 are as follows: Number of Exercise shares Price 20,000 $ 0.09 190,000 $ 0.20 300,000 $ 0.30 55,000 $ 0.38 1,386,670 $ 0.40 10,000 $ 0.45 613,550 $ 0.50 160,000 $ 0.60 15,000 $ 0.62 100,000 $ 0.75 10,000 $ 0.81 38,000 $ 1.00 2,898,220 At December 31, 2015, the Company had 1,801,780 unissued shares available under the Plan. Also, at December 31, 2015, the Company had $105,339 of total unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted average period of 9 years. Warrants Outstanding warrants to purchase common stock are as follows: Date of Issue Number of Warrants Exercise Price Expiration As of December 2014 4,653,325 $ 0.36 - $10.00 09/2016 - 10/2024 January-15 70,000 $ 0.30 - $0.50 01/2020 March-15 137,500 $ 0.10 - $0.75 03/2018 - 03/2022 April-15 6,160,000 $ 0.01 - $0.15 04/2018 - 04/2027 May-15 6,160,000 $ 0.125 - $0.23 05/2018 - 05/2022 June-15 300,000 $ 0.125 - $0.15 06/2018 July-15 1,445,000 $ 0.125 - $0.15 07/2018 Total as of December 31, 2015 18,925,825 We use the Black-Scholes option-pricing model to determine the fair value of warrants on the date of grant. In determining the fair value of warrants, we employed the following key assumptions: December 31, 2015 December 31, 2014 Risk-Free interest rate 0.28% - 1.72 % 0.28% - 2.97 % Expected dividend yield 0 % 0 % Volatility 166.10% - 204.66 % 182.81% - 222.30 % Expected life 3 - 7 years 3 - 10 years At December 31, 2015 and 2014, the weighted-average Black-Scholes value of warrants granted was $0.14 and $0.39, respectively. |
NOTE 10 - INCOME TAXES
NOTE 10 - INCOME TAXES | 12 Months Ended |
Dec. 31, 2015 | |
Income Tax Disclosure [Abstract] | |
Income Tax Disclosure [Text Block] | NOTE 10 – INCOME TAXES For the years ended December 31, 2015, and 2014, we incurred net operating losses and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At December 31, 2015, we had approximately $4,328,688 of net operating losses. The net operating loss carryforwards, if not utilized, will begin to expire in 2026. The components of our deferred tax assets/liabilities as of December 31, are as follows: 2015 2014 Deferred tax assets: Reserves and accruals $ 168,000 $ 114,000 Net operating loss carryforwards 1,943,000 1,472,000 Total deferred tax assets: 2,111,000 1,586,000 Deferred tax liabilities: Depreciation and amortization 6,000 8,000 Net deferred tax assets before valuation allowance 2,105,000 1,578,000 Less: Valuation allowance (2,105,000 ) (1,578,000 ) Net deferred tax assets $ - $ - For financial reporting purposes, we have incurred a loss in each period since inception. Based on the available objective evidence, including our history of losses, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, we provided for a full valuation allowance against our net deferred tax assets at December 31, 2015, and 2014. A reconciliation between the amount of income tax benefit determined by applying the applicable U.S. statutory income tax rate to pre-tax loss for the years ended December 31, is as follows: 2015 2014 Federal Statutory Rate $ (768,000 ) $ (781,000 ) Nondeductible expenses 241,000 529,000 Change in allowance on deferred tax assets (527,000 ) (252,000 ) $ - $ - |
NOTE 11 - COMMITMENTS AND CONTI
NOTE 11 - COMMITMENTS AND CONTINGENCIES | 12 Months Ended |
Dec. 31, 2015 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies Disclosure [Text Block] | NOTE 11 – COMMITMENTS AND CONTINGENCIES Leases The Company has a lease agreement with on its headquarters facilities that expires in May 2018. The lease terms include a base monthly rental rate of $3,343 per month, increasing to $3,410 in August 2016, and then $3,478 in August 2017. The Company has analyzed the requirement to straight-line the full value of the lease agreement over the life of the lease and has determined that there is no need to book a deferred rent liability as the amount is immaterial. Future minimum lease payments for all of our facilities amount to $57,422 for 2016, $58,298 for 2017 and $37,974 through August 2018. Rent expense for the years ended December 31, 2015 and 2014 was $55,464 and $47,988, respectively. Employment Agreements During 2015, the Company entered into employment agreements with its CEO, COO/CFO and CSO. Commencement of payment of the base salaries under these employment agreements was, and continues to be, conditional on fundraising results. Management determined that no base salary for the CEO or CSO would be accrued or paid for 2015, based primarily upon the financial needs of the Company through the end of that year. Payment of base salary commenced for the COO/CFO in December 2015. Litigation At December 31, 2015, we were and continue to be a party to litigation with respect to a note payable, with a face amount of $50,000 and the accrued interest thereon. Additionally, we are involved in arbitration with a former employee who has made claims against us, along with other potential allegations seeking approximately $93,000, plus punitive damages. In both cases, the Company will defend itself vigorously and reserves the right to make counter claims against the adversarial parties. Although we believe that these situations will be settled in due time, without material effect to the Company or its future operations, we can offer no assurance to that effect. |
NOTE 12 - CONCENTRATIONS AND CR
NOTE 12 - CONCENTRATIONS AND CREDIT RISK | 12 Months Ended |
Dec. 31, 2015 | |
Risks and Uncertainties [Abstract] | |
Concentration Risk Disclosure [Text Block] | NOTE 12 – CONCENTRATIONS AND CREDIT RISK Customers and Credit Concentrations During 2015 and 2014, approximately 42% and 47%, respectively, of our sales were to 5 customers. Accounts receivable for these customers accounted for 57% and 81% of total accounts receivable at December 31, 2015 and 2014, respectively. Vendor Concentrations During 2015, approximately 64% of our purchases were made from 5 vendors as compared to 46% during 2014. Accounts payable for these vendors accounted for 0.5% and 4% of total accounts payable at December 31, 2015 and 2014, respectively. |
NOTE 13 - SUBSEQUENT EVENTS
NOTE 13 - SUBSEQUENT EVENTS | 12 Months Ended |
Dec. 31, 2015 | |
Subsequent Events [Abstract] | |
Subsequent Events [Text Block] | NOTE 13 – SUBSEQUENT EVENTS During first quarter 2016, one investor exchanged his existing $50,000 note plus accrued interest of $9,500 into a new convertible note with a face value of $55,000. The note accrues interest at 8% per annum and is due on December 26, 2016. The note is convertible into shares of our common stock at a rate of $0.10 per share. Terms of issuance were not finalized until 2016 with an effective date of December 26, 2015. As consideration for exchanging the note, we issued the investor a three-year warrant to purchase 50,000 shares of common stock at $0.125 per share. We calculated a gain on exchange of the note in the amount of $4,500. We also calculated discount on the fair value of the warrants in the amount of $3,135 and will amortize this amount over the life of the loan. In addition, the investor exchanged two additional existing five-year warrants to purchase 50,000 shares each at $2 and $0.50, respectively for one three-year warrant to purchase 100,000 shares of common stock at $0.125 per share. We have also calculated the possible gain or loss on modification of these warrants and determined this amount to be immaterial to our financial statements. During first quarter of 2016, one investor converted his existing $10,000 note plus accrued interest of $1,133 into a three-year, 8% convertible debenture with a face value of $11,333, and convertible into shares of common stock at a rate of $0.10 per share. Terms of issuance were not finalized until 2016 with an effective date of December 31, 2015. Attached to the debenture is a three-year warrant to purchase 11,333 shares of common stock at $0.125 per share. We calculated a discount on the fair value of the warrant in the amount of $714 and will amortize it over the life of the debenture. During first quarter of 2016, one investor converted his existing $15,000 note into a three-year, 8% convertible debenture with a face value of $15,000, and convertible into shares of common stock at a rate of $0.10 per share. Terms of issuance were not finalized until 2016 with an effective date of November 3, 2015. Attached to the debenture is a three-year warrant to purchase 15,000 shares of common stock at $0.125 per share. We calculated a discount on the fair value of the warrant in the amount of $945 and will amortize it over the life of the debenture During first quarter of 2016, one investor converted his existing $10,000 note plus accrued interest of $1,208 into a new convertible three-year, 8% convertible debenture with a face value of $11,000, and convertible into shares of common stock at a rate of $0.10 per share. Terms of issuance were not finalized until 2016 with an effective date of October 16, 2015. Attached to the debenture is a three-year warrant to purchase 11,000 shares of our common stock at $0.125 per share. We calculated a discount on the fair value of the warrant in the amount of $945 and will amortize it over the life of the loan. We also calculated a gain on the exchange of the note in the amount of $208. During February 2016, we borrowed $20,000 by means of two one-year promissory notes in the amount of $10,000 each that accrue interest at the rate of 10% per annum. One of these $10,000 notes is with a related party. During February 2016, an investor exchanged 2,744 shares of Series A preferred stock for 27,440 shares of common stock. During March 2016, we issued two three-year, 8% convertible debentures in the amount of $50,000 and $25,000. The debentures are convertible into shares of common stock at the rate of $0.10 per share. Attached to each debenture is a three-year warrant to purchase 50,000 and 25,000 shares of our common stock at $0.125 per share. We calculated a discount on the fair value of the warrants in the amounts of $3,150 and $1,575, respectively, and will amortize these discounts over the life of the debentures. During April 2016, we issued a three-year, 8% convertible debenture in the amount of $100,000 and convertible into shares of common stock at the rate of $0.10 per share. Attached to the debenture is a three-year warrant to purchase 100,000 shares of our common stock at $0.125 per share. We calculated a discount on the fair value of the warrant in the amount of $6,300 and will amortize this over the life of the debenture. |
Accounting Policies, by Policy
Accounting Policies, by Policy (Policies) | 12 Months Ended |
Dec. 31, 2015 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of presentation and principles of consolidation The accompanying consolidated financial statements and related notes have been prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Material intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements include the accounts of Entia and Total Nutraceutical Solutions, a wholly-owned subsidiary, as of December 31, 2015 and 2014. |
Use of Estimates, Policy [Policy Text Block] | Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash We consider all highly liquid, short-term investments with original maturities of three months or less when purchased to be cash equivalents. |
Receivables, Policy [Policy Text Block] | Accounts receivable Accounts receivable are recorded at the invoiced amount, net of allowance for doubtful accounts. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses based on specific identification of accounts in our existing accounts receivable. Outstanding account balances are reviewed individually for collectibility. We determine the allowance based on historical write-off experience, customer specific facts and economic conditions. Bad debt expense is included in general and administrative expenses, if any. We generally consider accounts greater than 30 days old to be past due. Account balances are charged off against allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts was $5,736 and $30,022 at December 31, 2015 and 2014, respectively. |
Inventory, Policy [Policy Text Block] | Inventory Inventory consists of finished goods and raw materials to be used in the production of our dietary supplement products, is stated at the lower of cost or market using the average cost method. We regularly review our inventory on hand and, when necessary, record a provision for excess or obsolete inventory. The portion of inventory that is not expected to be used in production of our products for more than 12 months is a long-term asset. |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and equipment Property and equipment are recorded at cost. Additions and improvements that increase the value or extend the life of an asset are capitalized. Maintenance and repairs are expensed as incurred. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in the consolidated statement of operations. Depreciation is computed on a straight-line basis over the following estimated useful lives of the assets: Office equipment 3 years Production equipment 5 to 7 years Leasehold improvements Lesser of lease term or useful life of improvement |
Intangible Assets, Finite-Lived, Policy [Policy Text Block] | Patents Patents, once issued or purchased, are amortized using the straight-line method over their economic remaining useful lives. All internally developed process costs incurred to the point when a patent application is to be filed are expensed as incurred and classified as research and development costs. Patent application costs, generally legal costs, are capitalized pending disposition of the individual patent application, and are subsequently either amortized based on the initial patent life granted, generally 15 to 20 years for domestic patents and 5 to 20 years for foreign patents, or expensed if the patent application is rejected. The costs of defending and maintaining patents are expensed as incurred. Upon becoming fully amortized, the related cost and accumulated amortization are removed from the accounts. |
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | Licenses Licenses that allow us to use certain technology in the production of our products are amortized on a straight-line basis over their remaining useful life (typically 15-17 years). Long-lived assets, including licenses, property and equipment and patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We assess the recoverability of our long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives. We have recorded an impairment on our licenses in the amount of $110,000 and $27,080 on December 31, 2015 and 2014, respectively. |
Debt, Policy [Policy Text Block] | Discount on convertible notes payable We allocate the proceeds received from convertible notes between convertible notes payable and warrants, if applicable. The resulting discount for warrants is amortized using the effective interest method over the life of the debt instrument. After allocating a portion of the proceeds to the warrants, the effective conversion price of the convertible note payable can be determined. If the effective conversion price is lower than the market price at the date of issuance, a beneficial conversion feature is recorded as an additional discount to the convertible note payable. The beneficial conversion feature discount is amortized using the effective interest method over the life of the debt instrument. The amortization is recorded as interest expense on the consolidated statement of operations. |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair value of financial instruments The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable and accounts payable approximate their fair values determined based on level 1 inputs in the fair value hierarchy because of the short maturity of these instruments. Due to conversion features and other terms, it is not practical to estimate the fair value of notes payable and convertible notes. |
Fair Value Measurement, Policy [Policy Text Block] | Fair value measurements We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions. We do not have any assets or liabilities measured at fair value on a recurring or a non-recurring basis. Consequently, we did not have any fair value adjustments for assets and liabilities measured at fair value at December 31, 2015 or 2014, nor any gains or losses reported in the consolidated statement of operations that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date for the years ended December 31, 2015 and 2014. |
Revenue Recognition, Policy [Policy Text Block] | Revenue recognition We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectibility of amounts is reasonably assured. Revenues from the sale of products, including shipping and handling fees but excluding statutory taxes collected from customers, as applicable, are recognized when shipment has occurred. We sell our products directly to customers and distributors. Persuasive evidence of an arrangement is demonstrated via order and invoice, product delivery is evidenced by a bill of lading from the third party carrier and title transfers upon shipment, the sales price to the customer is fixed upon acceptance of the order and there is no separate sales rebate, discount, or volume incentive. Allowances for product returns, primarily in connection with one distribution agreement, are provided at the time the sale is recorded. This allowance is based upon historical return rates for the Company and relevant industry patterns, which reflects anticipated returns of unopened product in its original packaging to be received over a period of 120 days following the original sale. |
Shipping and Handling Cost, Policy [Policy Text Block] | Shipping and handling costs Amounts charged to customers for shipping products are included in revenues and the related costs are classified in cost of goods sold as incurred. In 2015 and 2014, we incurred $27,848 and $34,286, respectively, in shipping costs included in cost of goods sold. |
Advertising Costs, Policy [Policy Text Block] | Advertising costs Costs associated with the advertising of our products are expensed as incurred. |
Research and Development Expense, Policy [Policy Text Block] | Research and development Research and development costs are charged to expense as incurred. Research and development costs consist primarily of material and testing costs for research and development as well as research and development arrangements with unrelated third party research and development institutions. These research and development arrangements usually involve one specific research and development project. We may make non-refundable advances upon signing of these arrangements. Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or as the related services are performed. Management periodically evaluates whether the goods will be delivered or services will be rendered. If management does not expect the goods to be delivered or services to be rendered, the capitalized advance payment is charged to expense. Research and development expense was $ 73,394 |
Stockholders' Equity, Policy [Policy Text Block] | Equity instruments issued to parties other than employees for acquiring goods or services We account for all transactions in which goods or services are the consideration received for the issuance of equity instruments based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. Currently such transactions are primarily awards of warrants to purchase common stock. The fair value of each warrant award is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The assumptions used to determine the fair value of our warrants are as follows: - The expected life of warrants issued represents the period of time the warrants are expected to be outstanding. - The expected volatility is generally based on the historical volatility of comparable companies’ stock over the contractual life of the warrant. - The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual life of the warrant. - The expected dividend yield is based on our current dividend yield as the best estimate of projected dividend yield for periods within the contractual life of the warrant. During 2015 and 2014, we issued restricted common stock, warrants and non-statutory stock options to attorneys, scientific, marketing and financial consultants and our external contract accountants. The value of these instruments equal $384,922 of the total $589,616 for 2015 and $257,689 of the total $642,897 for 2014. |
Income Tax, Policy [Policy Text Block] | Income taxes We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in our consolidated statements of income in the period that includes the enactment date. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in our consolidated financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Should they occur, our policy is to classify interest and penalties related to tax positions as income tax expense. The tax years that are open to examination are 2012, 2013, 2014 and 2015. |
Earnings Per Share, Policy [Policy Text Block] | Net loss per common share Basic and diluted net loss per share has been computed by dividing our net loss by the weighted average number of common shares issued and outstanding. Convertible preferred stock, options and warrants to purchase our common stock as well as debt which are convertible into common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share for 2015 and 2014. The following table presents a reconciliation of basic loss per share and excluded dilutive securities: For the Years Ended 2015 2014 Numerator: Net loss allocable to common stockholders $ (2,260,050 ) $ (2,296,591 ) Denominator: Weighted-average common shares outstanding 24,289,381 9,442,352 Basic and diluted net loss per share $ (0.09 ) $ (0.24 ) Common stock warrants 18,925,825 7,110,701 Series A convertible preferred stock 1,913,070 2,008,070 Stock options 2,898,220 2,866,470 Convertible debt including interest 601,775 1,317,604 Excluded dilutive securities 24,338,890 13,302,845 |
Reclassification, Policy [Policy Text Block] | Reclassifications Certain reclassifications have been made to prior period financial statements and footnotes in order to conform to the current period's presentation. |
Segment Reporting, Policy [Policy Text Block] | Segments We have determined that we operate in one segment for financial reporting purposes. |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently issued accounting pronouncements In May 2014, the FASB issued new accounting guidance related to revenue recognition. This new standard will replace all current U.S. GAAP guidance on this topic and eliminate all industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective for Entia in the first quarter of 2018, and can be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. We are evaluating the impact of adopting this new accounting standard on our financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This update requires organizations to recognize lease assets and lease liabilities on the balance sheet and also disclose key information about leasing arrangements. This ASU is effective for annual reporting periods beginning on or after December 15, 2018, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual period. We are currently evaluating the impact the adoption of this ASU will have on our consolidated financial statements. |
NOTE 2 - SUMMARY OF SIGNIFICA22
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) [Line Items] | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | The following table presents a reconciliation of basic loss per share and excluded dilutive securities: For the Years Ended 2015 2014 Numerator: Net loss allocable to common stockholders $ (2,260,050 ) $ (2,296,591 ) Denominator: Weighted-average common shares outstanding 24,289,381 9,442,352 Basic and diluted net loss per share $ (0.09 ) $ (0.24 ) Common stock warrants 18,925,825 7,110,701 Series A convertible preferred stock 1,913,070 2,008,070 Stock options 2,898,220 2,866,470 Convertible debt including interest 601,775 1,317,604 Excluded dilutive securities 24,338,890 13,302,845 |
Estimated Useful Lives [Member] | |
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) [Line Items] | |
Property, Plant and Equipment [Table Text Block] | Depreciation is computed on a straight-line basis over the following estimated useful lives of the assets: Office equipment 3 years Production equipment 5 to 7 years Leasehold improvements Lesser of lease term or useful life of improvement |
NOTE 3 - INVENTORY (Tables)
NOTE 3 - INVENTORY (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventory, Current [Table Text Block] | Inventory consists of the following at: December 31, 2015 December 31, 2014 Raw materials $ 27,313 $ 202,591 Finished goods 219,074 43,849 246,387 246,440 Less reserve for excess and obsolete inventory (151,064 ) (151,064 ) 95,323 95,376 Less current portion (40,323 ) (48,043 ) $ 55,000 $ 47,333 |
NOTE 4 - PROPERTY AND EQUIPME24
NOTE 4 - PROPERTY AND EQUIPMENT (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Property, Plant and Equipment Table [Member] | |
NOTE 4 - PROPERTY AND EQUIPMENT (Tables) [Line Items] | |
Property, Plant and Equipment [Table Text Block] | Property and equipment, stated at cost, consists of the following at: December 31, 2015 December 31, 2014 Office equipment $ 31,658 $ 27,507 Production equipment 90,899 86,999 Leasehold improvements 16,328 16,328 138,885 130,834 Less: accumulated depreciation (106,199 ) (87,687 ) $ 32,686 $ 43,147 |
NOTE 5 - PATENTS AND LICENSES25
NOTE 5 - PATENTS AND LICENSES, NET (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Disclosure Text Block [Abstract] | |
Schedule of Finite-Lived Intangible Assets [Table Text Block] | The gross carrying amounts and accumulated amortization related to these intangible assets consist of the following at: December 31, 2015 December 31, 2014 Licenses and amortizable patents $ 97,244 $ 207,244 Unamortized patents 179,393 166,159 Accumulated amortization (44,053 ) (30,569 ) Patents and Licenses, net $ 232,584 $ 342,834 |
NOTE 6 - ACCOUNTS PAYABLE AND26
NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Payables and Accruals [Abstract] | |
Schedule of Accrued Liabilities [Table Text Block] | Accrued expenses (included with accounts payable) consisted of the following at: December 31, 2015 December 31, 2014 Executive compensation $ 327,285 $ 153,432 Other accruals 38,022 19,725 $ 365,307 $ 173,157 |
NOTE 7 - NOTES PAYABLE (Tables)
NOTE 7 - NOTES PAYABLE (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Debt Disclosure [Abstract] | |
Schedule of Debt [Table Text Block] | Notes payable consists of the following at: December 31, 2015 December 31, 2014 Notes payable - current 7.85% unsecured, $473 due monthly $ - $ 2,304 5.86% unsecured, $781 due monthly 2,687 - 4.15% unsecured, $3,436 due monthly 36,374 - 4.15% unsecured, $3,436 due monthly - 23,726 10.00% unsecured, interest only, due on demand. Note was settled on May 29, 2015 in exchange for 250,000 shares of common stock. In addition, 500,000 3-year warrants were granted and vested with an exercise price ranging from $0.125 - $0.15. We calculated and posted a loss on the settlement in the amount of $32,500. - 25,000 $ 39,061 $ 51,030 |
Convertible Debt [Table Text Block] | Convertible notes payable, net 8% secured due on December 26, 2015 (net of discount related to beneficial conversion feature of $0 in 2015 and $7,746 in 2014), convertible into preferred stock at $5.00 per share. During 2016, this note was exchanged with an effective date of December 26, 2015. Refer to Note 13 – Subsequent Events for further disclosure $ 50,000 $ 42,254 6% unsecured, convertible into common stock at $2.00 per share, due on demand 50,000 50,000 10% unsecured due December 31, 2015 (net of discount related to warrants of $0 in 2015 and $1,727 in 2014) convertible price to be determined by the purchase price paid by investors in future offerings, not to exceed $1.50 per share. During 2016, this note was exchanged with an effective date of December 31, 2015. Refer to Note 13 – Subsequent Events for further disclosure. 10,000 8,273 10% unsecured due October 16, 2015 (net of discount related to warrants of $0 in 2015 and $1,805 in 2014) convertible price to be determined by the purchase price paid by investors in future offerings, not to exceed $1.50 per share. During 2016, this note was exchanged with an effective date of October 16, 2015. Refer to Note 13 – Subsequent Events for further disclosure. 10,000 8,195 8% unsecured due November 25, 2018 (net of discount related to warrants of $3,019 in 2015 and $0 in 2014) convertible into common stock at $0.10 per share. 46,981 - 0% unsecured due November 3, 2015 (net of discount related to beneficial conversion feature of $0 in 2015 and $2,738 in 2014 and net of discount related to warrants of $0 in 2015 and $2,863 in 2014 and convertible into common stock at $0.30 per share.) During 2016, this note was exchanged with an effective date of November 3, 2015. Refer to Note 13 – Subsequent Events for further disclosure. 15,000 9,399 Nine convertible notes payable (net of debt discount of $90,076) with interest between 8% to 10% were paid in cash or converted into common stock during 2015. - 239,525 $ 181,981 $ 357,646 |
NOTE 9 - STOCKHOLDERS' EQUITY28
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Stockholders' Equity Note [Abstract] | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | The fair value of the option grants was calculated at the date of the grants using the Black-Scholes option pricing model with the following assumptions: December 31, 2015 December 31, 2014 Expected dividend yield - - Expected stock price volatility 187.7% - 201.79 % 182.94% - 216.96 % Risk-free interest rate 1.47% - 1.68 % 0.28% - 1.91 % Expected term (in years) 5 years 3 - 7 years Weighted-average granted date fair value $ 0.16 $ 0.45 |
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | A summary of option activity under the stock option plan as of December 31, 2015, and changes during the year then ended is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Price Exercise Contractual Term Intrinsic Shares Range Price (Years) Value Outstanding, December 31, 2013 2,352,099 $ 0.38 - $1.00 $ 0.51 7.90 199,505 Exercisable, December 31, 2013 1,810,344 $ 0.38 - $1.00 $ 0.52 7.88 138,707 Granted 624,571 $ 0.40-$0.75 $ 0.52 6.49 - Exercised - - $ - - - Expired/Forfeited 110,200 $ 0.40-$0.50 $ 0.48 9.51 - Outstanding, December 31, 2014 2,866,470 $ 0.30 - $1.00 $ 0.48 8.96 - Exercisable, December 31, 2014 2,321,001 $ 0.38 - $1.00 $ 0.47 9.50 - Granted 50,000 $ 0.09 - $0.20 $ 0.16 5.00 - Exercised - - $ - - - Expired/Forfeited 18,250 $ 0.40 - $0.50 $ 0.49 8.73 - Outstanding, December 31, 2015 2,898,220 $ .0.20 - $1.00 $ 0.43 11.25 - Exercisable, December 31, 2015 2,661,493 $ 0.096 - $1.00 $ 0.42 11.66 - |
Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Table Text Block] | The range of exercise prices for options outstanding under the 2010 Stock Incentive Plan at December 31, 2015 are as follows: Number of Exercise shares Price 20,000 $ 0.09 190,000 $ 0.20 300,000 $ 0.30 55,000 $ 0.38 1,386,670 $ 0.40 10,000 $ 0.45 613,550 $ 0.50 160,000 $ 0.60 15,000 $ 0.62 100,000 $ 0.75 10,000 $ 0.81 38,000 $ 1.00 2,898,220 |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Outstanding warrants to purchase common stock are as follows: Date of Issue Number of Warrants Exercise Price Expiration As of December 2014 4,653,325 $ 0.36 - $10.00 09/2016 - 10/2024 January-15 70,000 $ 0.30 - $0.50 01/2020 March-15 137,500 $ 0.10 - $0.75 03/2018 - 03/2022 April-15 6,160,000 $ 0.01 - $0.15 04/2018 - 04/2027 May-15 6,160,000 $ 0.125 - $0.23 05/2018 - 05/2022 June-15 300,000 $ 0.125 - $0.15 06/2018 July-15 1,445,000 $ 0.125 - $0.15 07/2018 Total as of December 31, 2015 18,925,825 |
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block] | In determining the fair value of warrants, we employed the following key assumptions: December 31, 2015 December 31, 2014 Risk-Free interest rate 0.28% - 1.72 % 0.28% - 2.97 % Expected dividend yield 0 % 0 % Volatility 166.10% - 204.66 % 182.81% - 222.30 % Expected life 3 - 7 years 3 - 10 years |
NOTE 10 - INCOME TAXES (Tables)
NOTE 10 - INCOME TAXES (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Income Tax Disclosure [Abstract] | |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | The components of our deferred tax assets/liabilities as of December 31, are as follows: 2015 2014 Deferred tax assets: Reserves and accruals $ 168,000 $ 114,000 Net operating loss carryforwards 1,943,000 1,472,000 Total deferred tax assets: 2,111,000 1,586,000 Deferred tax liabilities: Depreciation and amortization 6,000 8,000 Net deferred tax assets before valuation allowance 2,105,000 1,578,000 Less: Valuation allowance (2,105,000 ) (1,578,000 ) Net deferred tax assets $ - $ - |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | A reconciliation between the amount of income tax benefit determined by applying the applicable U.S. statutory income tax rate to pre-tax loss for the years ended December 31, is as follows: 2015 2014 Federal Statutory Rate $ (768,000 ) $ (781,000 ) Nondeductible expenses 241,000 529,000 Change in allowance on deferred tax assets (527,000 ) (252,000 ) $ - $ - |
NOTE 1 - ORGANIZATION AND OPE30
NOTE 1 - ORGANIZATION AND OPERATIONS (Details) - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 |
Disclosure Text Block [Abstract] | |||
Cash and Cash Equivalents, at Carrying Value | $ 24,133 | $ 99,462 | $ 36,886 |
NOTE 2 - SUMMARY OF SIGNIFICA31
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) | 12 Months Ended | |
Dec. 31, 2015USD ($) | Dec. 31, 2014USD ($) | |
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||
Allowance for Doubtful Accounts Receivable | $ 5,736 | $ 30,022 |
Impairment of Intangible Assets, Finite-lived | 110,000 | 27,080 |
Shipping, Handling and Transportation Costs | 27,848 | 34,286 |
Research and Development Expense | 73,394 | 24,523 |
Share-based Compensation | $ 589,616 | 642,897 |
Number of Operating Segments | 1 | |
Equity Issued for Services [Member] | ||
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||
Stock Issued During Period, Value, Issued for Services | $ 384,922 | $ 257,689 |
Domestic Patents [Member] | Minimum [Member] | ||
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||
Finite-Lived Intangible Asset, Useful Life | 15 years | |
Domestic Patents [Member] | Maximum [Member] | ||
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||
Finite-Lived Intangible Asset, Useful Life | 20 years | |
Foreign Patents [Member] | Minimum [Member] | ||
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||
Finite-Lived Intangible Asset, Useful Life | 5 years | |
Foreign Patents [Member] | Maximum [Member] | ||
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||
Finite-Lived Intangible Asset, Useful Life | 20 years | |
Technology-Based Intangible Assets [Member] | Minimum [Member] | ||
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||
Finite-Lived Intangible Asset, Useful Life | 15 years | |
Technology-Based Intangible Assets [Member] | Maximum [Member] | ||
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||
Finite-Lived Intangible Asset, Useful Life | 17 years |
NOTE 2 - SUMMARY OF SIGNIFICA32
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Property, Plant and Equipment, Estimated Useful Lives | 12 Months Ended |
Dec. 31, 2015 | |
Office Equipment [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, plant and equipment, useful life | 3 years |
Leasehold Improvements [Member] | |
Property, Plant and Equipment [Line Items] | |
Leasehold improvements | Lesser of lease term or useful life of improvement |
Minimum [Member] | Machinery and Equipment [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, plant and equipment, useful life | 5 years |
Maximum [Member] | Machinery and Equipment [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, plant and equipment, useful life | 7 years |
NOTE 2 - SUMMARY OF SIGNIFICA33
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Numerator: | ||
Net loss allocable to common stockholders (in Dollars) | $ (2,260,050) | $ (2,296,591) |
Denominator: | ||
Weighted-average common shares outstanding | 24,289,381 | 9,442,352 |
Basic and diluted net loss per share (in Dollars per share) | $ (0.09) | $ (0.24) |
Excluded dilutive securties | 24,338,890 | 13,302,845 |
Warrant [Member] | ||
Denominator: | ||
Excluded dilutive securties | 18,925,825 | 7,110,701 |
Convertble Preferred Shares [Member] | ||
Denominator: | ||
Excluded dilutive securties | 1,913,070 | 2,008,070 |
Equity Option [Member] | ||
Denominator: | ||
Excluded dilutive securties | 2,898,220 | 2,866,470 |
Convertible Debt Securities [Member] | ||
Denominator: | ||
Excluded dilutive securties | 601,775 | 1,317,604 |
NOTE 3 - INVENTORY (Details) -
NOTE 3 - INVENTORY (Details) - Schedule of Inventory - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 |
Schedule of Inventory [Abstract] | ||
Raw materials | $ 27,313 | $ 202,591 |
Finished goods | 219,074 | 43,849 |
246,387 | 246,440 | |
Less reserve for excess and obsolete inventory | (151,064) | (151,064) |
95,323 | 95,376 | |
Less current portion | (40,323) | (48,043) |
$ 55,000 | $ 47,333 |
NOTE 4 - PROPERTY AND EQUIPME35
NOTE 4 - PROPERTY AND EQUIPMENT (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Property, Plant and Equipment [Abstract] | ||
Depreciation | $ 18,512 | $ 23,605 |
NOTE 4 - PROPERTY AND EQUIPME36
NOTE 4 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 |
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | $ 138,885 | $ 130,834 |
Less: accumulated depreciation | (106,199) | (87,687) |
32,686 | 43,147 | |
Office Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 31,658 | 27,507 |
Machinery and Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 90,899 | 86,999 |
Leasehold Improvements [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | $ 16,328 | $ 16,328 |
NOTE 5 - PATENTS AND LICENSES37
NOTE 5 - PATENTS AND LICENSES, NET (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
NOTE 5 - PATENTS AND LICENSES, NET (Details) [Line Items] | ||
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) | $ 110,000 | $ 27,080 |
Licensing Agreements [Member] | ||
NOTE 5 - PATENTS AND LICENSES, NET (Details) [Line Items] | ||
Amortization of Intangible Assets | 13,484 | $ 14,442 |
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months | 4,396 | |
Finite-Lived Intangible Assets, Amortization Expense, Year Two | 4,396 | |
Finite-Lived Intangible Assets, Amortization Expense, Year Three | 4,396 | |
Finite-Lived Intangible Assets, Amortization Expense, Year Four | 4,396 | |
Finite-Lived Intangible Assets, Amortization Expense, Year Five | 4,396 | |
Finite-Lived Intangible Assets, Amortization Expense, after Year Five | $ 31,214 | |
Licensing Agreements [Member] | Minimum [Member] | ||
NOTE 5 - PATENTS AND LICENSES, NET (Details) [Line Items] | ||
Finite-Lived Intangible Asset, Useful Life | 15 years | |
Licensing Agreements [Member] | Maximum [Member] | ||
NOTE 5 - PATENTS AND LICENSES, NET (Details) [Line Items] | ||
Finite-Lived Intangible Asset, Useful Life | 17 years |
NOTE 5 - PATENTS AND LICENSES38
NOTE 5 - PATENTS AND LICENSES, NET (Details) - Schedule of Finite-Lived Intangible Assets - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 |
Finite-Lived Intangible Assets [Line Items] | ||
Accumulated amortization | $ (44,053) | $ (30,569) |
Patents and Licenses, net | 232,584 | 342,834 |
Licensing Agreements [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Intangilble assets, gross | 97,244 | 207,244 |
Patents [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Intangilble assets, gross | $ 179,393 | $ 166,159 |
NOTE 6 - ACCOUNTS PAYABLE AND39
NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accrued Liabilities - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 |
Schedule of Accrued Liabilities [Abstract] | ||
Executive compensation | $ 327,285 | $ 153,432 |
Other accruals | 38,022 | 19,725 |
$ 365,307 | $ 173,157 |
NOTE 7 - NOTES PAYABLE (Details
NOTE 7 - NOTES PAYABLE (Details) - USD ($) | Mar. 25, 2014 | Dec. 31, 2015 | Dec. 31, 2014 |
NOTE 7 - NOTES PAYABLE (Details) [Line Items] | |||
Line of Credit, Current | $ 58,195 | $ 16,179 | |
Line of Credit [Member] | |||
NOTE 7 - NOTES PAYABLE (Details) [Line Items] | |||
Line of Credit Facility, Maximum Borrowing Capacity | $ 60,000 | ||
Line of Credit Facility, Interest Rate at Period End | 6.50% | ||
Prime Rate [Member] | Line of Credit [Member] | |||
NOTE 7 - NOTES PAYABLE (Details) [Line Items] | |||
Debt Instrument, Basis Spread on Variable Rate | 3.00% |
NOTE 7 - NOTES PAYABLE (Detai41
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 |
Notes payable - current | ||
Notes payable | $ 39,061 | $ 51,030 |
Note Payable 1 [Member] | Loans Payable [Member] | ||
Notes payable - current | ||
Notes payable | 0 | 2,304 |
Note Payable 2 [Member] | Loans Payable [Member] | ||
Notes payable - current | ||
Notes payable | 2,687 | 0 |
Note Payable 3 [Member] | Loans Payable [Member] | ||
Notes payable - current | ||
Notes payable | 36,374 | 0 |
Note Payable 4 [Member] | Loans Payable [Member] | ||
Notes payable - current | ||
Notes payable | 0 | 23,726 |
Note Payable 5 [Member] | Loans Payable [Member] | ||
Notes payable - current | ||
Notes payable | $ 0 | $ 25,000 |
NOTE 7 - NOTES PAYABLE (Detai42
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items] | ||
Warrants granted | 4,653,325 | |
Note, loss on settlement | $ 32,500 | $ 169,187 |
Note Payable 1 [Member] | Loans Payable [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items] | ||
% | 7.85% | |
Due monthly | $ 473 | |
Note Payable 2 [Member] | Loans Payable [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items] | ||
% | 5.86% | |
Due monthly | $ 781 | |
Note Payable 3 [Member] | Loans Payable [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items] | ||
% | 4.15% | |
Due monthly | $ 3,436 | |
Note Payable 4 [Member] | Loans Payable [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items] | ||
% | 4.15% | |
Due monthly | $ 3,436 | |
Note Payable 5 [Member] | Loans Payable [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items] | ||
% | 10.00% | |
Due | Due on demand | |
Note settled in exchange for common stock | 250,000 | |
Warrants granted | 500,000 | |
Note, loss on settlement | $ 32,500 | |
Warrants | 3 years | |
Minimum [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items] | ||
Warrants, exercise price | $ 0.36 | |
Minimum [Member] | Note Payable 5 [Member] | Loans Payable [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items] | ||
Warrants, exercise price | 0.125 | |
Maximum [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items] | ||
Warrants, exercise price | 10 | |
Maximum [Member] | Note Payable 5 [Member] | Loans Payable [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items] | ||
Warrants, exercise price | $ 0.15 |
NOTE 7 - NOTES PAYABLE (Detai43
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 |
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items] | ||
Convertible Note Payable | $ 181,981 | $ 357,646 |
Convertible Note 1 [Member] | Convertible Notes Payable [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items] | ||
Convertible Note Payable | 50,000 | 42,254 |
Convertible Note 2 [Member] | Convertible Notes Payable [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items] | ||
Convertible Note Payable | 50,000 | 50,000 |
Convertible Note 3 [Member] | Convertible Notes Payable [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items] | ||
Convertible Note Payable | 10,000 | 8,273 |
Convertible Note 4 [Member] | Convertible Notes Payable [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items] | ||
Convertible Note Payable | 10,000 | 8,195 |
Convertible Note 5 [Member] | Convertible Notes Payable [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items] | ||
Convertible Note Payable | 46,981 | 0 |
Convertible Note 6 [Member] | Convertible Notes Payable [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items] | ||
Convertible Note Payable | 15,000 | 9,399 |
Nine Covertible Notes Payable [Member] | Convertible Notes Payable [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items] | ||
Convertible Note Payable | $ 0 | $ 239,525 |
NOTE 7 - NOTES PAYABLE (Detai44
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) - Convertible Notes Payable [Member] - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Convertible Note 1 [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items] | ||
% | 8.00% | 8.00% |
Due | Dec. 26, 2015 | Dec. 26, 2015 |
Discount related to beneficial conversion feature | $ 0 | $ 7,746 |
Convertible at | $ 5 | $ 5 |
Convertible Note 2 [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items] | ||
% | 6.00% | 6.00% |
Convertible at | $ 2 | $ 2 |
Due | Due on demand | Due on demand |
Convertible Note 3 [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items] | ||
% | 10.00% | 10.00% |
Due | December 2,015 | December 2,015 |
Discount related to warrants | $ 0 | $ 1,727 |
Convertible price | convertible price to be determined by the purchase price paid by investors in future offerings, not to exceed $1.50 per share | convertible price to be determined by the purchase price paid by investors in future offerings, not to exceed $1.50 per share |
Convertible Note 4 [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items] | ||
% | 10.00% | 10.00% |
Due | October 2,015 | October 2,015 |
Discount related to warrants | $ 0 | $ 1,805 |
Convertible price | convertible price to be determined by the purchase price paid by investors in future offerings, not to exceed $1.50 per share | convertible price to be determined by the purchase price paid by investors in future offerings, not to exceed $1.50 per share |
Convertible Note 5 [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items] | ||
% | 8.00% | |
Due | Nov. 25, 2018 | |
Convertible at | $ 0.10 | |
Discount related to warrants | $ 0 | |
Convertible Note 6 [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items] | ||
% | 0.00% | 0.00% |
Discount related to beneficial conversion feature | $ 0 | $ 2,738 |
Convertible at | $ 0.30 | $ 0.30 |
Due | November 2,015 | November 2,015 |
Discount related to warrants | $ 0 | $ 2,863 |
Nine Covertible Notes Payable [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items] | ||
Discount related to beneficial conversion feature | $ 90,076 | |
Minimum [Member] | Nine Covertible Notes Payable [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items] | ||
% | 8.00% | |
Maximum [Member] | Nine Covertible Notes Payable [Member] | ||
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items] | ||
% | 10.00% |
NOTE 8 - RELATED PARTY TRANSA45
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) - USD ($) | Apr. 17, 2015 | Jul. 01, 2014 | Sep. 30, 2014 | Dec. 31, 2014 |
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items] | ||||
Class of Warrant or Rights, Granted (in Shares) | 4,653,325 | |||
Director [Member] | Convertible Debt [Member] | ||||
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items] | ||||
Debt Instrument, Interest Rate, Stated Percentage | 0.00% | |||
Debt Instrument, Face Amount | $ 15,000 | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 15,000 | |||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 0.50 | |||
Warrants, Fair Value of Warrants, Granted | $ 5,445 | |||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.50 | |||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 7,545 | |||
Director [Member] | Note Extension [Member] | Convertible Debt [Member] | ||||
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items] | ||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 0.20 | |||
Warrants, Fair Value of Warrants, Granted | $ 3,435 | |||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.30 | |||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 3,285 | |||
Class of Warrant or Rights, Granted (in Shares) | 15,000 | |||
Director [Member] | Issuance to Director #1 [Member] | ||||
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items] | ||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | 200,000 | |||
Stock Issued During Period, Value, Restricted Stock Award, Gross | $ 40,000 | |||
Director [Member] | Issucance to Director #2 [Member] | ||||
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items] | ||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | 200,000 | |||
Stock Issued During Period, Value, Restricted Stock Award, Gross | $ 40,000 | |||
Chief Executive Officer [Member] | ||||
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items] | ||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | 600,000 | |||
Stock Issued During Period, Value, Restricted Stock Award, Gross | $ 120,000 | |||
Chief Operating Officer [Member] | ||||
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items] | ||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | 550,000 | |||
Stock Issued During Period, Value, Restricted Stock Award, Gross | $ 110,000 |
NOTE 9 - STOCKHOLDERS' EQUITY46
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - USD ($) | Jan. 01, 2015 | Jan. 01, 2012 | May. 26, 2011 | Sep. 17, 2010 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | Feb. 15, 2012 |
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items] | ||||||||
Preferred Stock, Shares Authorized | 5,000,000 | 5,000,000 | ||||||
Preferred Stock, Liquidation Preference Per Share (in Dollars per share) | $ 5 | |||||||
Warrants, Grants in Period, Weighted-Average Grant Date Fair Value (in Dollars per share) | $ 0.14 | $ 0.39 | ||||||
2010 Stock Incentive Plan [Member] | ||||||||
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 4,700,000 | 15,000,000 | 4,650,000 | 1,550,000 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized | 50,000 | 500,000 | 1,500,000 | 1,500,000 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 1,801,780 | |||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars) | $ 105,339 | |||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 9 years | |||||||
2010 Stock Incentive Plan [Member] | Automatic Increase in Shares Authorized [Member] | ||||||||
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized | 100,000 | 100,000 | ||||||
Stock Issued for Services Rendered [Member] | ||||||||
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items] | ||||||||
Stock Issued During Period, Shares, Share-based Compensation, Gross | 150,000,000 | |||||||
Stock Issued During Period, Value, Share-based Compensation, Gross (in Dollars) | $ 0.001 | |||||||
Series A Preferred Stock [Member] | ||||||||
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items] | ||||||||
Preferred Stock, Shares Authorized | 350,000 | 350,000 | 350,000 | |||||
Preferred Stock, No Par Value (in Dollars per share) | $ 0.001 | |||||||
Preferred Stock, Conversion Basis | one-for-ten | |||||||
Minimum [Member] | 2010 Stock Incentive Plan [Member] | ||||||||
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 4 years | |||||||
Maximum [Member] | 2010 Stock Incentive Plan [Member] | ||||||||
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 15 years |
NOTE 9 - STOCKHOLDERS' EQUITY47
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Fair Value Measurements, Stock Options, Valuation Assumptions - $ / shares | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Fair Value Measurements, Stock Options, Valuation Assumptions [Line Items] | ||
Expected dividend yield | 0.00% | 0.00% |
Expected term (in years) | 5 years | |
Weighted-average granted date fair value (in Dollars per share) | $ 0.16 | $ 0.45 |
Minimum [Member] | ||
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Fair Value Measurements, Stock Options, Valuation Assumptions [Line Items] | ||
Expected stock price volatility | 187.70% | 182.94% |
Risk-free interest rate | 1.47% | 0.28% |
Expected term (in years) | 3 years | |
Maximum [Member] | ||
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Fair Value Measurements, Stock Options, Valuation Assumptions [Line Items] | ||
Expected stock price volatility | 201.79% | 216.96% |
Risk-free interest rate | 1.68% | 1.91% |
Expected term (in years) | 7 years |
NOTE 9 - STOCKHOLDERS' EQUITY48
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Stock Options, Activity - USD ($) | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Stock Options, Activity [Line Items] | |||
Options Outstanding, Number of Shares (in Shares) | 2,866,470 | 2,352,099 | |
Options Outstanding, Weighted Average Exercise Price | $ 0.48 | $ 0.51 | |
Options Outstanding, Weighted Average Remaining Contractual Term | 11 years 3 months | 8 years 350 days | 7 years 328 days |
Options Outstanding, Average Intrinsic Value (in Dollars) | $ 199,505,000,000 | ||
Options Exercisable, Number of Shares (in Shares) | 2,321,001 | 1,810,344 | |
Options Exercisable, Weighted Average Exercise Price | $ 0.47 | $ 0.52 | |
Options Exercisable, Weighted Average Remaining Contractual Term | 11 years 240 days | 9 years 6 months | 7 years 321 days |
Options Exercisable, Average Intrinsic Value (in Dollars) | $ 138,707,000,000 | ||
Options Granted, Number of Shares (in Shares) | 50,000 | 624,571 | |
Options Granted, Weighted Average Exercise Price | $ 0.16 | $ 0.52 | |
Options Granted, Weighted Average Remaining Contractual Term | 5 years | 6 years 178 days | |
Options Exercised, Number of Shares (in Shares) | 0 | 0 | |
Options Exercised, Weighted Average Exercise Price | $ 0 | $ 0 | |
Options Exercisted, Average Intrinsic Value (in Dollars) | $ 0 | $ 0 | |
Options Expired, Number of Shares (in Shares) | 18,250 | 110,200 | |
Options Expired, Weighted Average Exercise Price | $ 0.49 | $ 0.48 | |
Options Expired, Weighted Average Remaining Contractual Term | 8 years 266 days | 9 years 186 days | |
Options Outstanding, Number of Shares (in Shares) | 2,898,220 | 2,866,470 | |
Options Outstanding, Weighted Average Exercise Price | $ 0.43 | $ 0.48 | |
Options Exercisable, Number of Shares (in Shares) | 2,661,493 | 2,321,001 | |
Options Exercisable, Weighted Average Exercise Price | $ 0.42 | $ 0.47 | |
Minimum [Member] | |||
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Stock Options, Activity [Line Items] | |||
Options Outstanding, Exercise Price | 0.30 | $ 0.38 | |
Options Exercisable, Exercise Price | 0.38 | 0.38 | |
Options Granted, Exercise Price | 0.09 | 0.40 | |
Options Expired, Exercise Price | 0.40 | 0.40 | |
Options Outstanding, Exercise Price | 0.20 | 0.30 | |
Options Exercisable, Exercise Price | 0.096 | 0.38 | |
Maximum [Member] | |||
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Stock Options, Activity [Line Items] | |||
Options Outstanding, Exercise Price | 1 | 1 | |
Options Exercisable, Exercise Price | 1 | $ 1 | |
Options Granted, Exercise Price | 0.20 | 0.75 | |
Options Expired, Exercise Price | 0.50 | 0.50 | |
Options Outstanding, Exercise Price | 1 | 1 | |
Options Exercisable, Exercise Price | $ 1 | $ 1 |
NOTE 9 - STOCKHOLDERS' EQUITY49
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range - $ / shares | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2012 |
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items] | |||
Number of Options Outstanding | 2,898,220 | 2,866,470 | 2,352,099 |
Options Exerciable at $0.09 [Member] | |||
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items] | |||
Number of Options Outstanding | 20,000 | ||
Exercise Price of Options Outstanding (in Dollars per share) | $ 0.09 | ||
Options Exercisable at $0.20 [Member] | |||
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items] | |||
Number of Options Outstanding | 190,000 | ||
Exercise Price of Options Outstanding (in Dollars per share) | $ 0.20 | ||
Options Exercisable at $0.30 [Member] | |||
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items] | |||
Number of Options Outstanding | 300,000 | ||
Exercise Price of Options Outstanding (in Dollars per share) | $ 0.30 | ||
Options Exercisable at $0.38 [Member] | |||
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items] | |||
Number of Options Outstanding | 55,000 | ||
Exercise Price of Options Outstanding (in Dollars per share) | $ 0.38 | ||
Options Exercisable at $0.40 [Member] | |||
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items] | |||
Number of Options Outstanding | 1,386,670 | ||
Exercise Price of Options Outstanding (in Dollars per share) | $ 0.40 | ||
Options Exercisable at $0.45 [Member] | |||
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items] | |||
Number of Options Outstanding | 10,000 | ||
Exercise Price of Options Outstanding (in Dollars per share) | $ 0.45 | ||
Options Exercisable at $0.50 [Member] | |||
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items] | |||
Number of Options Outstanding | 613,550 | ||
Exercise Price of Options Outstanding (in Dollars per share) | $ 0.50 | ||
Options Exercisable at $0.60 [Member] | |||
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items] | |||
Number of Options Outstanding | 160,000 | ||
Exercise Price of Options Outstanding (in Dollars per share) | $ 0.60 | ||
Options Exercisable at $0.62 [Member] | |||
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items] | |||
Number of Options Outstanding | 15,000 | ||
Exercise Price of Options Outstanding (in Dollars per share) | $ 0.62 | ||
Options Exercisable at $0.75 [Member] | |||
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items] | |||
Number of Options Outstanding | 100,000 | ||
Exercise Price of Options Outstanding (in Dollars per share) | $ 0.75 | ||
Options Exercisable at $0.81 [Member] | |||
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items] | |||
Number of Options Outstanding | 10,000 | ||
Exercise Price of Options Outstanding (in Dollars per share) | $ 0.81 | ||
Options Exercisable at $1.00 [Member] | |||
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items] | |||
Number of Options Outstanding | 38,000 | ||
Exercise Price of Options Outstanding (in Dollars per share) | $ 1 |
NOTE 9 - STOCKHOLDERS' EQUITY50
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Stockholders' Equity Note, Warrants - $ / shares | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding (in Shares) | 4,653,325 | |
Warrants Expiration | 09/2016 - 10/2024 | |
Warrants Issued January 2015 [Member] | ||
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding (in Shares) | 70,000 | |
Warrants Expiration | 01/2020 | |
Warrants Issued March 2015 [Member] | ||
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding (in Shares) | 137,500 | |
Warrants Expiration | 03/2018 - 03/2022 | |
Warrants Issued April 2015 [Member] | ||
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding (in Shares) | 6,160,000 | |
Warrants Expiration | 04/2018 - 04/2027 | |
Warrants Issued May 2015 [Member] | ||
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding (in Shares) | 6,160,000 | |
Warrants Expiration | 05/2018 - 05/2022 | |
Warrants Issued June 2015 [Member] | ||
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding (in Shares) | 300,000 | |
Warrants Expiration | 06/2018 | |
Warrants Issued July 2015 [Member] | ||
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding (in Shares) | 1,445,000 | |
Warrants Expiration | 07/2018 | |
Total as of December 31, 2015 (in Shares) | 18,925,825 | |
Minimum [Member] | ||
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding, Exercise Price | $ 0.36 | |
Minimum [Member] | Warrants Issued January 2015 [Member] | ||
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding, Exercise Price | $ 0.30 | |
Minimum [Member] | Warrants Issued March 2015 [Member] | ||
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding, Exercise Price | 0.10 | |
Minimum [Member] | Warrants Issued April 2015 [Member] | ||
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding, Exercise Price | 0.01 | |
Minimum [Member] | Warrants Issued May 2015 [Member] | ||
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding, Exercise Price | 0.125 | |
Minimum [Member] | Warrants Issued June 2015 [Member] | ||
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding, Exercise Price | 0.125 | |
Minimum [Member] | Warrants Issued July 2015 [Member] | ||
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding, Exercise Price | 0.125 | |
Maximum [Member] | ||
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding, Exercise Price | $ 10 | |
Maximum [Member] | Warrants Issued January 2015 [Member] | ||
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding, Exercise Price | 0.50 | |
Maximum [Member] | Warrants Issued March 2015 [Member] | ||
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding, Exercise Price | 0.75 | |
Maximum [Member] | Warrants Issued April 2015 [Member] | ||
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding, Exercise Price | 0.15 | |
Maximum [Member] | Warrants Issued May 2015 [Member] | ||
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding, Exercise Price | 0.23 | |
Maximum [Member] | Warrants Issued June 2015 [Member] | ||
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding, Exercise Price | 0.15 | |
Maximum [Member] | Warrants Issued July 2015 [Member] | ||
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding, Exercise Price | $ 0.15 |
NOTE 9 - STOCKHOLDERS' EQUITY51
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Fair Value Measurements, Warrants, Valuation Assumptions | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] | ||
Expected dividend yield | 0.00% | 0.00% |
Minimum [Member] | ||
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] | ||
Risk-Free interest rate | 0.28% | 0.28% |
Volatility | 166.10% | 182.81% |
Expected life | 3 years | 3 years |
Maximum [Member] | ||
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] | ||
Risk-Free interest rate | 1.72% | 2.97% |
Volatility | 204.66% | 222.30% |
Expected life | 7 years | 10 years |
NOTE 10 - INCOME TAXES (Details
NOTE 10 - INCOME TAXES (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Income Tax Disclosure [Abstract] | |
Operating Loss Carryforwards | $ 4,328,688 |
Operating Loss Carryforwards, Expiration Date | 2,026 |
NOTE 10 - INCOME TAXES (Detai53
NOTE 10 - INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 |
Deferred tax assets: | ||
Reserves and accruals | $ 168,000 | $ 114,000 |
Net operating loss carryforwards | 1,943,000 | 1,472,000 |
Total deferred tax assets: | 2,111,000 | 1,586,000 |
Deferred tax liabilities: | ||
Depreciation and amortization | 6,000 | 8,000 |
Net deferred tax assets before valuation allowance | 2,105,000 | 1,578,000 |
Less: Valuation allowance | (2,105,000) | (1,578,000) |
Net deferred tax assets | $ 0 | $ 0 |
NOTE 10 - INCOME TAXES (Detai54
NOTE 10 - INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Schedule of Effective Income Tax Rate Reconciliation [Abstract] | ||
Federal Statutory Rate | $ (768,000) | $ (781,000) |
Nondeductible expenses | 241,000 | 529,000 |
Change in allowance on deferred tax assets | (527,000) | (252,000) |
$ 0 | $ 0 |
NOTE 11 - COMMITMENTS AND CON55
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||
Operating Leases, Future Minimum Payments Due, Next Twelve Months | $ 57,422 | |
Operating Leases, Future Minimum Payments, Due in Two Years | 58,298 | |
Operating Leases, Future Minimum Payments, Due in Three Years | 37,974 | |
Operating Leases, Rent Expense, Net | 55,464 | $ 47,988 |
Litigation, Note Payable [Member] | ||
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||
Debt Instrument, Face Amount | 50,000 | |
Litigation, Former Employee [Member] | ||
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||
Loss Contingency, Damages Sought, Value | 93,000 | |
Land and Building [Member] | Operating Lease, Monthly Rental Expense, Year 1 [Member] | ||
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||
Operating Leases, Rent Expense, Minimum Rentals | 3,343 | |
Land and Building [Member] | Operating Lease, Monthly Rental Expense, Year 2 [Member] | ||
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||
Operating Leases, Rent Expense, Minimum Rentals | 3,410 | |
Land and Building [Member] | Operating Lease, Monthly Rental Expense, Year 3 [Member] | ||
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||
Operating Leases, Rent Expense, Minimum Rentals | $ 3,478 |
NOTE 12 - CONCENTRATIONS AND 56
NOTE 12 - CONCENTRATIONS AND CREDIT RISK (Details) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Five Vendors [Member] | Cost of Goods, Total [Member] | Supplier Concentration Risk [Member] | ||
NOTE 12 - CONCENTRATIONS AND CREDIT RISK (Details) [Line Items] | ||
Concentration Risk, Percentage | 64.00% | 46.00% |
Five Vendors [Member] | Liabilities, Total [Member] | Supplier Concentration Risk [Member] | ||
NOTE 12 - CONCENTRATIONS AND CREDIT RISK (Details) [Line Items] | ||
Concentration Risk, Percentage | 0.50% | 4.00% |
Five Customers [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | ||
NOTE 12 - CONCENTRATIONS AND CREDIT RISK (Details) [Line Items] | ||
Concentration Risk, Percentage | 42.00% | 47.00% |
Five Customers [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member] | ||
NOTE 12 - CONCENTRATIONS AND CREDIT RISK (Details) [Line Items] | ||
Concentration Risk, Percentage | 57.00% | 81.00% |
NOTE 13 - SUBSEQUENT EVENTS (De
NOTE 13 - SUBSEQUENT EVENTS (Details) | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||||
Apr. 30, 2016USD ($)$ / sharesshares | Mar. 31, 2016USD ($)$ / sharesshares | Feb. 29, 2016shares | Mar. 31, 2016USD ($)$ / sharesshares | Dec. 31, 2015USD ($)$ / sharesshares | Dec. 31, 2014USD ($)$ / sharesshares | Feb. 16, 2016USD ($) | |
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||
Class of Warrant or Rights, Granted (in Shares) | shares | 4,653,325 | ||||||
Gains (Losses) on Restructuring of Debt | $ 6,906 | $ 103,021 | |||||
Subsequent Event [Member] | Series A Preferred Stock [Member] | |||||||
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||
Conversion of Stock, Shares Converted (in Shares) | shares | 2,744 | ||||||
Conversion of Stock, Shares Issued (in Shares) | shares | 27,440 | ||||||
Convertible Notes Payable [Member] | Subsequent Event [Member] | |||||||
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||
Debt Instrument, Face Amount | $ 100,000 | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | ||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares | $ 0.10 | ||||||
Warrants, Term of Warrants | 3 years | ||||||
Class of Warrant or Rights, Granted (in Shares) | shares | 100,000 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares | $ 0.125 | ||||||
Warrants, Fair Value of Warrants, Granted | $ 6,300 | ||||||
Debt Instrument, Term | 3 years | ||||||
Two Warrants Exchanged for One Warrant [Member] | Subsequent Event [Member] | |||||||
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||
Warrants, Term of Warrants | 3 years | ||||||
Class of Warrant or Rights, Granted (in Shares) | shares | 100,000 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares | $ 0.125 | $ 0.125 | |||||
Warrant Exercisable at $2.00 [Member] | Two Warrants Exchanged for One Warrant [Member] | |||||||
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||
Warrants, Term of Warrants | 5 years | ||||||
Class of Warrant or Rights, Granted (in Shares) | shares | 50,000 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares | $ 2 | ||||||
Warrant Exercisable at $0.50 [Member] | Two Warrants Exchanged for One Warrant [Member] | |||||||
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||
Warrants, Term of Warrants | 5 years | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares | $ 0.50 | ||||||
Restructure of Note Payable to Convertible Note Payable [Member] | Notes Payable, Other Payables [Member] | |||||||
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||
Number of Investors | 1 | ||||||
Debt Instrument, Face Amount | $ 50,000 | ||||||
Interest Payable | $ 9,500 | ||||||
Restructure of Note Payable to Convertible Note Payable [Member] | Convertible Notes Payable [Member] | Subsequent Event [Member] | |||||||
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||
Debt Instrument, Face Amount | $ 55,000 | $ 55,000 | |||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | 8.00% | |||||
Debt Instrument, Maturity Date | Dec. 26, 2016 | ||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares | $ 0.10 | $ 0.10 | |||||
Warrants, Term of Warrants | 3 years | ||||||
Class of Warrant or Rights, Granted (in Shares) | shares | 50,000 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares | $ 0.125 | $ 0.125 | |||||
Gains (Losses) on Restructuring of Debt | $ 4,500 | ||||||
Warrants, Fair Value of Warrants, Granted | 3,135 | ||||||
Restructure of Note Payable to Convertible Note Payable #2 [Member] | Notes Payable, Other Payables [Member] | |||||||
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||
Number of Investors | 1 | ||||||
Debt Instrument, Face Amount | $ 10,000 | ||||||
Interest Payable | $ 1,133 | ||||||
Restructure of Note Payable to Convertible Note Payable #2 [Member] | Convertible Notes Payable [Member] | Subsequent Event [Member] | |||||||
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||
Debt Instrument, Face Amount | $ 11,333 | $ 11,333 | |||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | 8.00% | |||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares | $ 0.10 | $ 0.10 | |||||
Warrants, Term of Warrants | 3 years | ||||||
Class of Warrant or Rights, Granted (in Shares) | shares | 11,333 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares | $ 0.125 | $ 0.125 | |||||
Warrants, Fair Value of Warrants, Granted | $ 714 | ||||||
Debt Instrument, Term | 3 years | ||||||
Restructure of Note Payable to Convertible Note Payable #3 [Member] | Notes Payable, Other Payables [Member] | |||||||
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||
Number of Investors | 1 | ||||||
Debt Instrument, Face Amount | $ 15,000 | ||||||
Restructure of Note Payable to Convertible Note Payable #3 [Member] | Convertible Notes Payable [Member] | Subsequent Event [Member] | |||||||
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||
Debt Instrument, Face Amount | $ 15,000 | $ 15,000 | |||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | 8.00% | |||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares | $ 0.10 | $ 0.10 | |||||
Warrants, Term of Warrants | 3 years | ||||||
Class of Warrant or Rights, Granted (in Shares) | shares | 15,000 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares | $ 0.125 | $ 0.125 | |||||
Warrants, Fair Value of Warrants, Granted | $ 945 | ||||||
Debt Instrument, Term | 3 years | ||||||
Restructure of Note Payable to Convertible Note Payable #4 [Member] | Notes Payable, Other Payables [Member] | |||||||
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||
Number of Investors | 1 | ||||||
Debt Instrument, Face Amount | $ 10,000 | ||||||
Interest Payable | $ 1,208 | ||||||
Restructure of Note Payable to Convertible Note Payable #4 [Member] | Convertible Notes Payable [Member] | Subsequent Event [Member] | |||||||
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||
Debt Instrument, Face Amount | $ 11,000 | $ 11,000 | |||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | 8.00% | |||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares | $ 0.10 | $ 0.10 | |||||
Warrants, Term of Warrants | 3 years | ||||||
Class of Warrant or Rights, Granted (in Shares) | shares | 11,000 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares | $ 0.125 | $ 0.125 | |||||
Gains (Losses) on Restructuring of Debt | $ 208 | ||||||
Warrants, Fair Value of Warrants, Granted | $ 945 | ||||||
Debt Instrument, Term | 3 years | ||||||
Note Payable 2 [Member] | Notes Payable, Other Payables [Member] | Subsequent Event [Member] | |||||||
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||
Debt Instrument, Face Amount | $ 20,000 | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | ||||||
Note Payable 1 [Member] | Notes Payable, Other Payables [Member] | Subsequent Event [Member] | |||||||
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||
Debt Instrument, Face Amount | $ 10,000 | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | ||||||
Convertible Note 1 [Member] | Convertible Notes Payable [Member] | |||||||
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | 8.00% | |||||
Debt Instrument, Maturity Date | Dec. 26, 2015 | Dec. 26, 2015 | |||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares | $ 5 | $ 5 | |||||
Convertible Note 1 [Member] | Convertible Notes Payable [Member] | Subsequent Event [Member] | |||||||
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||
Debt Instrument, Face Amount | $ 50,000 | $ 50,000 | |||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | 8.00% | |||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares | $ 0.10 | $ 0.10 | |||||
Warrants, Term of Warrants | 3 years | ||||||
Class of Warrant or Rights, Granted (in Shares) | shares | 50,000 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares | $ 0.125 | $ 0.125 | |||||
Warrants, Fair Value of Warrants, Granted | $ 3,150 | ||||||
Convertible Note 2 [Member] | Convertible Notes Payable [Member] | |||||||
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||
Debt Instrument, Interest Rate, Stated Percentage | 6.00% | 6.00% | |||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares | $ 2 | $ 2 | |||||
Convertible Note 2 [Member] | Convertible Notes Payable [Member] | Subsequent Event [Member] | |||||||
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||
Debt Instrument, Face Amount | $ 25,000 | $ 25,000 | |||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares | $ 0.10 | $ 0.10 | |||||
Warrants, Term of Warrants | 3 years | ||||||
Class of Warrant or Rights, Granted (in Shares) | shares | 25,000 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares | $ 0.125 | $ 0.125 | |||||
Warrants, Fair Value of Warrants, Granted | $ 1,575 |